ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
-10.88%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$46.7M
AUM Growth
+$46.7M
(-75%)
Cap. Flow
-$123M
Cap. Flow
% of AUM
-264.71%
Top 10 Holdings %
Top 10 Hldgs %
69.4%
Holding
38
New
8
Increased
2
Reduced
12
Closed
16
Top Buys
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$2.73M |
| 2 |
DexCom
DXCM
|
$2.2M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
$1.88M |
| 4 |
AMRN
Amarin Corp
AMRN
|
$1.58M |
| 5 |
Tandem Diabetes Care
TNDM
|
$1.12M |
Top Sells
| 1 |
Inogen
INGN
|
$12.8M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$11.6M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$10.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$9.12M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$8.56M |
Sector Composition
| 1 | Healthcare | 91.36% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $4.42M | 9.47% | 250,584 -479,856 | -66% | -$8.46M |
|
2
PTC Therapeutics
PTCT
$3.92B
| $4.07M | 8.73% | 120,449 -160,093 | -57% | -$5.41M |
|
|
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.03M | 8.64% | 150,299 -375,431 | -71% | -$10.1M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.64M | 7.8% | 75,011 -239,206 | -76% | -$11.6M |
|
5
Gilead Sciences
GILD
$140B
| $3.39M | 7.27% | 53,486 -94,795 | -64% | -$6.01M |
|
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $3.32M | 7.12% | 49,262 -127,063 | -72% | -$8.56M |
|
|
GWPH
7
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $2.73M | 5.85% | +23,729 | New | +$2.73M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.5M | 5.35% | 47,902 -78,753 | -62% | -$4.11M |
|
|
9
DexCom
DXCM
$29.5B
| $2.2M | 4.72% | +14,770 | New | +$2.2M |
|
10
Natera
NTRA
$23.1B
| $2.07M | 4.44% | 63,112 -154,787 | -71% | -$5.08M |
|
|
11
Bio-Rad Laboratories Class A
BIO
$8.06B
| $1.88M | 4.02% | +5,638 | New | +$1.88M |
|
|
XLRN
12
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.88M | 4.02% | 47,453 -35,020 | -42% | -$1.38M |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $1.58M | 3.4% | +104,509 | New | +$1.58M |
|
14
CRISPR Therapeutics
CRSP
$4.71B
| $1.52M | 3.26% | 37,141 -60,358 | -62% | -$2.47M |
|
|
ATRS
15
DELISTED
Antares Pharma, Inc.
ATRS
| $1.26M | 2.71% | 377,399 +101,974 | +37% | +$341K |
|
|
NCNA
16
NuCana
NCNA
$6.09M
| $1.19M | 2.55% | 164,366 +1,952 | +1% | +$14.1K |
|
|
17
Tandem Diabetes Care
TNDM
$845M
| $1.12M | 2.4% | +18,995 | New | +$1.12M |
|
18
Verrica Pharmaceuticals
VRCA
$52.8M
| $1.1M | 2.35% | 74,301 -58,519 | -44% | -$864K |
|
19
Twist Bioscience
TWST
$1.63B
| $913K | 1.96% | 38,218 -133,685 | -78% | -$3.19M |
|
|
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $745K | 1.6% | +16,272 | New | +$745K |
|
21
Heron Therapeutics
HRTX
$207M
| $727K | 1.56% | +39,273 | New | +$727K |
|
22
Penumbra
PEN
$10.6B
| $363K | 0.78% | +2,700 | New | +$363K |
|
23
AbbVie
ABBV
$372B
| – | – | -14,406 | Closed | -$1.05M |
|
24
Adaptive Biotechnologies
ADPT
$2.01B
| – | – | -22,500 | Closed | -$1.09M |
|
25
Ascendis Pharma
ASND
$11.8B
| – | – | -3,800 | Closed | -$438K |
|